Next generation treatments for metastatic breast cancer

Despite the effectiveness observed with endocrine agents and the availability of CDK4/6 inhibitors for metastatic treatment, there is a requirement for studies investigating agents like OP-1250. This necessity arises from the fact that tumors can develop resistance to therapies. Additionally, certain endocrine agents that are used after treatment with CDK4/6 inhibitors do not achieve the desired level of effectiveness.[1]

OP-1250 is a type of medication that can be taken by mouth. It works by completely blocking the estrogen receptor, which is involved in the growth of certain types of breast cancer. It also prevents the receptor from carrying out its normal functions and causes it to break down. Scientists believe that OP-1250 may be more effective than other medications that only partially block the receptor. In lab studies, OP-1250 has shown to be effective against both mutated and non-mutated forms of breast cancer. These findings have led to ongoing clinical trials to test the effectiveness of OP-1250 in patients with advanced breast cancer who have not responded to other treatments. Early results from a phase I trial showed that a small percentage of patients had a positive response to the medication, with some experiencing tumor shrinkage or stabilization.

Other mechanisms of different drug classes:

Adopted by Lloyd MR et al.

Ongoing clinical trials of next-generation endocrine therapies in the metastatic, adjuvant, and neoadjuvant setting. [1]

Adopted by Lloyd MR et al.

[1] Alison D Parisian, Leslie Hodges-Gallagher, Richard Sun, Susanna Barratt, Gopinath S Palanisamy, Julia Lawrence, Pamela Klein, David C Myles, Cyrus L Harmon, Peter J Kushner. The complete estrogen receptor antagonist OP-1250 can combine with HER2 inhibition to inhibit estrogen receptor-driven cellular proliferation and shrink xenograft tumors in ER+/HER2+ breast cancer models [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-08-07.

[2]Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Ther Adv Med Oncol. 2022 Jul 30;14:17588359221113694. doi: 10.1177/17588359221113694. PMID: 35923930; PMCID: PMC9340905.